Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Type/Product Area | Terms/Details (Date) |
JUNE | |||
Almirall SA (Spain; LSE:OKWR) | Basilea Pharmaceutica AG (Switzerland) | Distribution agreement for Toctino, a once-daily oral treatment for severe chronic hand eczema unresponsive to topical corticocosteroids, in selected European markets and Mexico | Basilea will be eligible for up-front and milestone payments totaling $33.3M (6/16) |
Biovail Corp. (Canada; NYSE: BVF) | Kyowa Hakko Kirin Co. Ltd. (Japan) | License deal to acquire U.S. and Canadian rights to commercialize products containing istradefylline to treat Parkinson's disease | BLS paid an up-front fee of $10M and could pay up to $20M in development milestones through FDA approval and up to an additional $35M in sales-based milestones; BLS also will make tiered royalty payments of up to 30% on net commercial sales (6/4) |
Sirion Therapeutics Inc.* | Bausch + Lomb | Agreement acquiring U.S. rights to Zirgan, which was approved in 2009 as a topical antiviral against acute hepatic keratitis | Financial terms were not disclosed (6/4) |
Talecris Biotherapeutics Holdings Corp. (TLCR) | Novartis AG (Switzerland) | Co-promotion deal to jointly market and sell their respective post-exposure rabies products | Financial terms were not disclosed (6/16) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
The date indicated refers to the BioWorld Today issue in which the news item can be found. | |||
* Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
LSE = London Stock Exchange; NYSE = New York Stock Exchange. |